Profile data is unavailable for this security.
About the company
Amneal Pharmaceuticals, Inc., is a fully integrated global essential medicine company. The Company is engaged in the development, manufacturing, and distribution of a diverse portfolio of approximately 270 pharmaceutical products, primarily within the United States. The Company’s Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products and transdermal across a broad range of therapeutic categories. The Company's Specialty segment’s portfolio includes central nervous system disorders (Parkinson’s disease, spasticity, migraine), endocrinology (hypothyroidism), and other therapeutic areas. The Company’s AvKARE segment provides pharmaceuticals, medical and surgical products, and services to government, retail, and institutional markets.
- Revenue in USD (TTM)2.68bn
- Net income in USD-184.45m
- Incorporated2023
- Employees7.70k
- LocationAmneal Pharmaceuticals Inc400 Crossing Boulevard, 3rd FloorBRIDGEWATER 08807United StatesUSA
- Websitehttps://amneal.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tarsus Pharmaceuticals Inc | 129.62m | -134.34m | 1.77bn | 244.00 | -- | 7.49 | -- | 13.67 | -3.76 | -3.76 | 3.58 | 6.22 | 0.4022 | 6.37 | 7.51 | 531,233.60 | -41.68 | -31.56 | -48.37 | -33.82 | 92.97 | -- | -103.64 | -242.59 | 5.38 | -- | 0.2319 | -- | -32.42 | -- | -118.86 | -- | 279.39 | -- |
| Harmony Biosciences Holdings Inc | 681.88m | 122.63m | 1.87bn | 246.00 | 15.52 | 3.13 | 12.73 | 2.74 | 2.11 | 2.11 | 11.75 | 10.46 | 0.7994 | 24.26 | 9.17 | 2,771,866.00 | 14.38 | 7.46 | 17.12 | 9.08 | 78.65 | 80.58 | 17.98 | 10.46 | 3.20 | -- | 0.2345 | 0.00 | 32.93 | -- | -28.99 | -- | -25.31 | -- |
| Endo Inc | -100.00bn | -100.00bn | 1.91bn | 3.00k | -- | 1.04 | -- | -- | -- | -- | -- | 23.99 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 1.52 | -- | 0.5697 | -- | -13.25 | -- | 15.87 | -- | -- | -- |
| Supernus Pharmaceuticals Inc | 651.97m | 59.71m | 1.99bn | 652.00 | 33.82 | 1.98 | 13.95 | 3.06 | 1.07 | 1.07 | 11.71 | 18.24 | 0.4962 | 0.9689 | 4.54 | 999,957.10 | 4.54 | 4.95 | 5.83 | 6.41 | 89.04 | 88.61 | 9.16 | 12.84 | 1.98 | -- | 0.00 | -- | -8.95 | 8.24 | -97.83 | -58.81 | -8.17 | -- |
| Ligand Pharmaceuticals Inc | 152.42m | 45.24m | 2.11bn | 58.00 | 45.97 | 2.49 | 26.10 | 13.83 | 2.43 | 2.43 | 8.25 | 44.84 | 0.1768 | 0.4689 | 4.34 | 2,627,966.00 | 5.25 | 12.32 | 5.37 | 12.99 | 93.52 | 81.65 | 29.68 | 80.32 | 11.81 | -- | 0.00003 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Amphastar Pharmaceuticals Inc | 723.55m | 157.72m | 2.13bn | 1.76k | 14.67 | 2.93 | 10.10 | 2.95 | 3.01 | 3.01 | 13.79 | 15.04 | 0.4684 | 2.83 | 5.60 | 410,873.90 | 10.28 | 9.42 | 11.88 | 11.56 | 52.98 | 47.83 | 21.95 | 15.23 | 2.61 | 9.42 | 0.4506 | 0.00 | 29.14 | 16.94 | 50.51 | -- | -4.00 | -- |
| Twist Bioscience Corp | 312.97m | -208.73m | 2.44bn | 923.00 | -- | 5.12 | -- | 7.80 | -3.60 | -3.60 | 5.39 | 8.03 | 0.4501 | 6.40 | 7.93 | 339,083.40 | -30.02 | -28.50 | -33.49 | -31.56 | 42.61 | 39.40 | -66.69 | -93.82 | 4.54 | -- | 0.00 | -- | 27.69 | 41.91 | -2.01 | -- | -19.22 | -- |
| Catalyst Pharmaceuticals Inc | 460.48m | 142.80m | 2.52bn | 167.00 | 18.04 | 3.82 | 13.99 | 5.48 | 1.17 | 1.17 | 3.78 | 5.54 | 0.777 | 4.34 | 8.66 | 2,757,377.00 | 24.10 | 25.42 | 27.94 | 29.81 | 86.32 | 85.63 | 31.01 | 30.87 | 4.92 | -- | 0.00 | 0.00 | 85.90 | 280.39 | -14.05 | -- | 20.21 | -- |
| Amneal Pharmaceuticals Inc | 2.68bn | -184.45m | 2.60bn | 7.70k | -- | -- | 32.33 | 0.9712 | -0.6835 | -0.6835 | 9.08 | -0.3016 | 0.75 | 2.96 | 3.73 | 348,106.50 | -4.10 | -4.80 | -5.45 | -5.93 | 35.34 | 34.76 | -5.46 | -9.00 | 0.8372 | 1.26 | 1.01 | -- | 8.20 | 7.56 | 35.38 | -- | -6.55 | -- |
| Vericel Corp | 226.84m | 3.55m | 2.83bn | 314.00 | 740.18 | 10.96 | 317.66 | 12.46 | 0.0774 | 0.0774 | 4.69 | 5.23 | 0.6403 | 4.56 | 5.14 | 722,433.10 | 1.00 | -3.07 | 1.12 | -3.50 | 71.47 | 67.87 | 1.56 | -4.49 | 4.23 | -- | 0.0009 | -- | 20.17 | 16.80 | 80.96 | -- | 59.35 | -- |
| PTC Therapeutics, Inc. | 900.66m | -453.20m | 3.24bn | 988.00 | -- | -- | -- | 3.59 | -5.94 | -5.94 | 11.79 | -13.70 | 0.5807 | 1.97 | 4.93 | 911,603.30 | -29.22 | -26.71 | -45.34 | -33.46 | 92.20 | 93.94 | -50.32 | -83.80 | 2.04 | -0.7925 | 1.79 | -- | 34.20 | 28.78 | -12.09 | -- | 32.00 | -- |
| Apellis Pharmaceuticals Inc | 715.22m | -250.10m | 3.42bn | 702.00 | -- | 14.15 | -- | 4.78 | -2.04 | -2.04 | 5.81 | 1.94 | 0.8316 | 0.8814 | 3.19 | 1,018,828.00 | -29.08 | -73.88 | -37.24 | -90.03 | 86.47 | -- | -34.97 | -326.49 | 3.73 | -9.20 | 0.656 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
Data as of Nov 21 2024. Currency figures normalised to Amneal Pharmaceuticals Inc's reporting currency: US Dollar USD
27.22%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Credit Suisse Securities (USA) LLC (Broker)as of 30 Sep 2024 | 21.27m | 6.87% |
| The Vanguard Group, Inc.as of 30 Sep 2024 | 14.23m | 4.60% |
| BlackRock Fund Advisorsas of 30 Sep 2024 | 11.15m | 3.60% |
| Rubric Capital Management LPas of 30 Sep 2024 | 10.72m | 3.46% |
| Citadel Advisors LLCas of 30 Sep 2024 | 8.89m | 2.87% |
| Dimensional Fund Advisors LPas of 30 Sep 2024 | 4.23m | 1.37% |
| Neuberger Berman Investment Advisers LLCas of 30 Sep 2024 | 3.79m | 1.22% |
| Geode Capital Management LLCas of 30 Sep 2024 | 3.79m | 1.22% |
| SSgA Funds Management, Inc.as of 30 Sep 2024 | 3.51m | 1.14% |
| Nantahala Capital Management LLCas of 30 Sep 2024 | 2.67m | 0.86% |
More ▼
Data from 30 Sep 2024 - 30 Sep 2024Source: FactSet Research Systems Inc.
